Home > IRINOTECAN Hydrochloride Injection, USP*
Product Image
Please see full prescribing and safety information, including boxed warning, for IRINOTECAN vials.

Available in:

  • 40 mg per 2 mL single-use vials
  • 100 mg per 5 mL single-use vials

Benefits:

  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

Downloads:

PreventIV

IRINOTECAN Hydrochloride Injection, USP*

Brand Name Equivalent: CAMPTOSAR® (CAMPTOSAR is a registered trademark of Yakult Honsha Company, Ltd.)
Therapeutic Category: Antineoplastic Agent

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Yellow and black cytotoxic caution flag designed to alert healthcare workers who handle the product
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
NDC
#25021		 Description Strength Fill
Volume 		Concentration Container
Size 		Closure Unit
of Sale
230-02 Amber Glass Vial 40 mg 2 mL 20 mg per mL 2 mL 13 mm 1
230-05 Amber Glass Vial 100 mg 5 mL 20 mg per mL 7 mL 20 mm 1
WARNING: DIARRHEA AND MYELOSUPPRESSION
  • Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan hydrochloride injection and reduce subsequent doses if severe diarrhea occurs.
  • Severe myelosuppression may occur.